SCHEMBL2832086

SCHEMBL2832086

Cc1ccc(S(=O)(=O)Oc2ccccc2C(C)C(=O)OCc2ccccc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.49
MAPT P10636 3/20 0.46
PSEN1 P49768 1/20 0.46
PSEN2 P49810 1/20 0.46
APH1B Q8WW43 1/20 0.46
NCSTN Q92542 1/20 0.46
APH1A Q96BI3 1/20 0.46
PSENEN Q9NZ42 1/20 0.46
MAPK1 P28482 1/20 0.44
CA1 P00915 4/20 0.44
CA2 P00918 4/20 0.44
ACHE P22303 1/20 0.44
GAA P10253 2/20 0.43
MEN1 O00255 1/20 0.43
ESR1 P03372 1/20 0.43
KMT2A Q03164 1/20 0.43
ESR2 Q92731 1/20 0.43
P2RX7 Q99572 5/20 0.42
ALDH1A1 P00352 2/20 0.41
ELANE P08246 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2838943 0.93 CA1 (0.47) LMNAMAPTMAPK1CA1CA2
SCHEMBL3583111 0.88 LMNA (0.48) LMNAMAPTMAPK1GAAMEN1
SCHEMBL1824374 0.84 CA1 (0.53) LMNAMAPTCA1CA2ACHE
SCHEMBL2832079 0.84 LMNA (0.49) LMNAMAPTMAPK1GAAMEN1
SCHEMBL2833082 0.84 LMNA (0.51) LMNAMAPTMAPK1GAAMEN1
SCHEMBL2831635 0.83 SMN1; SMN2 (0.51) LMNAMAPTMAPK1GAAMEN1
SCHEMBL2838892 0.83 CA1 (0.49) LMNAMAPK1CA1CA2ACHE
SCHEMBL1823668 0.82 LMNA (0.44) LMNAMAPTMAPK1ACHEGAA
SCHEMBL1825308 0.81 PSEN1 (0.52) LMNAMAPTPSEN1PSEN2APH1B
SCHEMBL1825213 0.81 LMNA (0.46) LMNAMAPTMAPK1GAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2161254-B1 Intermediate for preparing a biaryl compound SUMITOMO CHEMICAL CO (JP) 2014-08-13 EP disclosed
US-7714157-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-05-11 US disclosed
EP-2161254-A1 Intermediate for preparing a biaryl compound Sumitomo Chemical Company, Limited (JP) 2010-03-10 EP disclosed
US-20070270603-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2007-11-22 US disclosed
US-7271280-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-18 US disclosed
EP-1481967-A1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS Sumitomo Chemical Company, Limited (JP) 2004-12-01 EP disclosed
US-20040158093-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158093-A1 Process for preparing a biaryl compound CYP1B1, REL, CYP2F1 LMNA 1802/4885MAPT 4712/4885PSEN1 3804/4885
US-20070270603-A1 Process for preparing a biaryl compound CYP4A11, CYP4B1, CYP51A1 LMNA 1130/4885MAPT 2237/4885PSEN1 2197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.